GETTING TO ACCESS: Time to Access: Too fast, too slow, or just right?
•
1 gefällt mir•159 views
GETTING TO ACCESS Innovative approaches to innovative medicines March 29, 2017
Empfohlen
Empfohlen
Weitere ähnliche Inhalte
Ähnlich wie GETTING TO ACCESS: Time to Access: Too fast, too slow, or just right?
Ähnlich wie GETTING TO ACCESS: Time to Access: Too fast, too slow, or just right? (20)
Mehr von Canadian Organization for Rare Disorders
Mehr von Canadian Organization for Rare Disorders (20)
Kürzlich hochgeladen
Kürzlich hochgeladen (20)
GETTING TO ACCESS: Time to Access: Too fast, too slow, or just right?
- 1. Time toAccess: Too fast, too slow, or just right? Presented by George Wyatt, Executive Senior Consultant Data Analysis by Dr. Eric Siu, Senior Manager March 29, 2017
- 2. InnomarConsulting™ § Innomar Strategies acquired Wyatt Health (Dec.‘16) - Formed InnomarCounsulting™ § Plus Innomar Strategies offers: - Regulatory Support - 3rd Party Logistics - Pharmacy Services and Networks - HealthForward Payer Services - Nursing and Clinics - Patient Support Programs, and more Full Canadian Reimbursement Services Full Service Solutions 3/29/17 CONFIDENTIAL2
- 3. The Parties and Responsibilities Time Frame Who’s Responsible 1. Regulatory Period (prior to NOC) Pharmaceutical Company 2. Reimbursement Evaluation HTA Body (CDR, pCODR, INESSS) Private Payers 3. “Price/Value” negotiations pCPA & Pharmaceutical Company 4. Reimbursement Decision Public and Private Payers 3/29/17 CONFIDENTIAL3
- 4. Median Days: NOC to CDR Submission 3/29/17 CONFIDENTIAL4 11 37 32 55 31 91 64 52 61 55 41 27 5 -61 36 43 8 126 202 222 72 97 52 42 116 83 37 70 -100 -50 0 50 100 150 200 250 Days(Median) All DRD
- 5. Median Days: CDR Submission to CDR Recommendation 3/29/17 CONFIDENTIAL5 181 187 180 212 202 194 193 202 181 202 301 232 189 201 195 189 167 182 210 160 202 203 197 262 362 215 207 0 50 100 150 200 250 300 350 400 Days (Median) All DRD
- 6. CDR not afraid to change § 24th edition of Submission Guidelines - Changes every year, except 2012 – when CDEC codes changes § 17th edition of CDR Procedures § 120 CDR Updates § Nearly 500 submissions § Over 400 recommendations - Positive type recommendations increasing 3/29/17 CONFIDENTIAL6
- 8. Median Days: CDR Recommendation to Active pCPA 3/29/17 CONFIDENTIAL8 79 75 0 10 20 30 40 50 60 70 80 90 All DRD Days (Median)
- 9. Median Days: Active pCPA to pCPA Completion 3/29/17 CONFIDENTIAL9 152 184 0 20 40 60 80 100 120 140 160 180 200 All DRD Days (Median) pCPA Total = 259 days pCPA Total = 231 days
- 10. Median Days: CDR Recommendation to Reimbursement 3/29/17 CONFIDENTIAL10 293 219 307 341 319 320 219 355 290 290 -47 280 466 719 429 443 351 456 386 0 455 438 -104 422 -200 -100 0 100 200 300 400 500 600 700 800 AB BC MB NB NL NS ON PEI SK AVG (w/o QC) QC AVG Days (Median) All DRD
- 11. Poster at 2010 CADTH Symposium 3/29/17 CONFIDENTIAL11
- 12. Median Days: CDR Recommendation to Reimbursement 3/29/17 CONFIDENTIAL12 2004-2009 – Extracted from Poster Presented at CADTH Symposium – April 2010
- 13. What’s happening & What does it mean for patients § Time from Recommendation to Reimbursement is Increasing - Too slow for many patients - <200 days (2004-2009) to 280-290 days (2004-2017) = 9+ months - Drugs for Rare Diseases is now 422-438 days = 14+ months § pCPA process has added Time - Responsibility: pCPA and Pharmaceutical Companies > Strong preparation is very important § More Warning Clouds - pCPA (drug plans) may not negotiate when drug receives HTA Recommendation with Clinical Criteria and/or Conditions > Perceived no unmet medical need > Payers may not have resources § Every delay can hurt a deserving patient - We can’t relax – we need to be persistent with our message 3/29/17 CONFIDENTIAL13